BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23549870)

  • 1. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
    Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
    Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
    Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
    Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
    Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
    Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
    Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
    BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
    Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
    BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
    Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
    Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
    Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 mRNA overexpression in high grade prostate tumors: lack of association with TMPRSS2-ERG rearrangement.
    de Muga S; Hernández S; Salido M; Lorenzo M; Agell L; Juanpere N; Lorente JA; Serrano S; Lloreta J
    Cancer Biomark; 2012-2013; 12(1):21-30. PubMed ID: 23321466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer.
    Schwartzman J; Mongoue-Tchokote S; Gibbs A; Gao L; Corless CL; Jin J; Zarour L; Higano C; True LD; Vessella RL; Wilmot B; Bottomly D; McWeeney SK; Bova GS; Partin AW; Mori M; Alumkal J
    Epigenetics; 2011 Oct; 6(10):1248-56. PubMed ID: 21946329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
    Kang GH; Lee S; Lee HJ; Hwang KS
    J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.
    Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A
    Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulation of an imprinted gene network in prostate cancer.
    Ribarska T; Goering W; Droop J; Bastian KM; Ingenwerth M; Schulz WA
    Epigenetics; 2014 May; 9(5):704-17. PubMed ID: 24513574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.
    Kim JH; Dhanasekaran SM; Prensner JR; Cao X; Robinson D; Kalyana-Sundaram S; Huang C; Shankar S; Jing X; Iyer M; Hu M; Sam L; Grasso C; Maher CA; Palanisamy N; Mehra R; Kominsky HD; Siddiqui J; Yu J; Qin ZS; Chinnaiyan AM
    Genome Res; 2011 Jul; 21(7):1028-41. PubMed ID: 21724842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.